Investors

ARVO

May 7 - May 11, 2017

Poster presentation:
A Phase 1/2 multidose, dose escalation study to evaluate RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular AMD (NVAMD) RXI-109: Self-delivering RNAi (sd-rxRNA) compound targeting connective tissue growth factor (CTGF) This poster presentation will show that RXI-109 has been found to be safe and well tolerated following intravitreal injection in subjects with advanced neovascular or wet age-related advanced macular degeneration (AMD) based on data collected thus far. The Study (RXI-109-1501) is still ongoing and the safety and clinical activity will be evaluated upon completion of the study. RXI-109 has the potential to fill an unmet medical need by reducing the retinal scarring that often results in AMD patients. RXI-109 is being developed as a potential therapeutic to preserve vision for a longer period of time as compared to standard of care treatments alone.

Date and Time: Tuesday, May 9, from 11:00 AM to 12:45 PM EDT
Presented by: Natalie Gagne
Poster: #3210, Retina Session 342-AMD Clinical Research 2, Poster Area B

Location

Baltimore Convention Center, Maryland

Investors